Long-Term Safety and Efficacy of Esketamine in Patients With Treatment-Resistant Depression: A Review of Interim Results From the SUSTAIN-3 Trial

This publication is sponsored by Janssen Pharmaceuticals, Inc.

The ongoing SUSTAIN-3 trial (NCT02782104) investigates the long-term safety and efficacy of individualized, intermittently dosed esketamine nasal spray used with an oral antidepressant in patients with treatment-resistant depression. This clinical brief reviews both the established short-term efficacy and safety profile of esketamine nasal spray and the study design and interim analysis results of the SUSTAIN-3 study.